Roche has acquired rights to an obesity therapy by Denmark's Zealand Pharma in a collaboration deal worth up to $5.3 billion, ...

Acne creams from retailers including Walgreens, La Roche-Posay and Proactiv have been voluntarily recalled due to elevated ...

Roche Holding said it would pay Danish biotechnology research company Zealand Pharma up to $5.3 billion under an agreement to ...

U.S. health officials are asking retailers to pull a small number of acne creams from their store shelves after government ...

The inquiry is the latest effort by the European Commission and European countries to scrutinize potential antitrust behavior ...

Parent company La Roche-Posay has pulled the Effaclar Duo Acne Spot Treatment from L'Oreal's lineup, due to a cancer-causing ...

Roche moved to enter the booming weight-loss drug market now dominated by Novo Nordisk and Eli Lilly. The Swiss ...

Roche is paying $1.65 billion in confirmed upfront fees to add to its burgeoning obesity pipelin | Roche is paying $1.65 ...

Roche and Zealand reason petrelintide could deliver weight loss comparable to glucagon-like peptide 1 (GLP-1) receptor agonists but without the side effects associated with GLP-1 drugs.

Swiss pharmaceutical giant Roche said Wednesday that it had struck a deal worth up to $5.3 billion to develop Zealand Pharma’s obesity drug candidate.

The FDA tested 95 products containing benzoyl peroxide, an ingredient widely used to treat acne that can form benzene as a byproduct. It found that six products could have more benzene than usual.